

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
CS-2047 TETANUS VACCINE
OBTAINS CLINICAL TRIAL APPROVAL

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that, the Absorbed Tetanus Vaccine (the “**CS-2047 Tetanus Vaccine**”) developed by the Group has obtained clinical trial approval granted by the National Medical Products Administration of the People's Republic of China to initiate relevant clinical trials in people aged 18 years old and above for the prevention of tetanus.

The CS-2047 Tetanus Vaccine is fermented with animal-free culture medium and safer, and the stable industrial scale processes have been identified. This vaccine is mainly used for non-neonatal tetanus prevention, which will further enrich the Company's product pipeline and enhance its core competitiveness.

We cannot guarantee that we will be able to develop, or ultimately commercialize CS-2047 Tetanus Vaccine successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, July 27, 2023

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.